Lanxess AG Overview
LANXESS is a mid-cap German specialty chemicals group. It was carved out of Bayer in 2004 and over two decades has transformed from a cyclical rubber- and plastics-heavy portfolio into a three-segment specialty chemicals company: Consumer Protection, Specialty Additives and Advanced Intermediates.
The transformation has been completed in sequence. The rubber exit came via ARLANXEO (2016–2018). Engineering plastics were contributed to the Envalior joint venture (2023). Urethane Systems was sold to UBE (April 2025). LANXESS now describes itself as a pure specialty-chemicals provider.
The group holds globally relevant positions in several niches:
-
bromine-based flame retardants
-
biocides and material protection
-
benzoic acid and benzoate derivatives
-
ion-exchange resins (Lewatit)
-
iron-oxide pigments (Bayferrox)
-
lubricant and rubber additives
-
aromatic intermediates for agrochemicals
The investment case today is a deleveraging and self-help story. FY2025 sales were EUR 5.67bn and EBITDA pre was EUR 510m. Net debt is about 4x EBITDA pre, and the rating is sub-investment-grade at Moody's. The equity value is now comparable to the book value of LANXESS's 40.94% Envalior stake. Value realisation hinges on the Envalior exit (2027/2028), EUR 150m of structural cost savings and a European chemicals recovery.
What the company does
LANXESS develops, manufactures and markets three groups of products:
-
chemical intermediates (aromatics, amines, nitro and chlorinated aromatics, inorganic pigments)
-
additives (flame retardants, plasticisers, lubricant additives, rubber chemicals)
-
consumer protection products (biocides, disinfectants, preservatives, aroma chemicals, benzoates, ion-exchange resins, custom synthesis)
Following the April 2025 Urethane Systems sale, the group reports three segments: Consumer Protection (CP), Specialty Additives (SA) and Advanced Intermediates (AI). It also holds a 40.94% equity-accounted stake in Envalior, the engineering-materials joint venture with Advent International.
Company's own description (paraphrased from corporate boilerplate and the 2024 Annual Report). LANXESS describes itself as a leading specialty chemicals company whose core business is the development, manufacturing and marketing of chemical intermediates, additives and consumer protection products. It operates in around 32 countries.
Business model and revenue model
| Revenue model element | Characterisation |
|---|---|
| Product vs. service mix | Close to 100% product sales (B2B chemical products sold by weight or volume). Service-like revenue is limited to custom manufacturing (toll and exclusive synthesis at Saltigo) and application and technical support bundled with products. |
| Subscription / licensing | Not material; no licensing revenue is disclosed |
| Contracting | Mix of annual and multi-year supply agreements (agro intermediates, custom synthesis) and spot or quarterly pricing (commodity-linked intermediates, pigments). Raw-material and energy pass-through clauses apply in parts of the portfolio. |
| Pricing model | Cost-plus with indexation in intermediates. Value-based pricing in specialties (biocides, flame retardants, ion-exchange resins). Periodic list-price increases, e.g. a 6–8% increase on Lewatit resins in spring 2026. |
Value-chain position
LANXESS sits mid-chain. It buys petrochemical feedstocks (benzene, toluene, chlorine, ammonia, cyclohexane) and minerals (bromine brines at El Dorado, Arkansas; iron sources for pigments). It converts these into intermediates and functional additives that customers formulate into their own end products. These customers include agrochemical majors, coatings and construction-materials producers, plastics compounders, lubricant blenders, tyre makers, and personal-care and household brands.
A significant share of Advanced Intermediates output is captive or quasi-captive: it feeds downstream LANXESS units (Saltigo, MPP, Polymer Additives) in integrated German Verbund sites at Leverkusen, Krefeld-Uerdingen and Dormagen.
Customer types and end-markets
| End-market | Exposure (qualitative) | Comment |
|---|---|---|
| Agrochemicals | High (Saltigo, AII aromatic intermediates, MPP actives) | Agro is about 70–80% of Saltigo sales (Q2 2026 call). Generic agro is under Chinese and Indian price pressure. |
| Construction | High (Bayferrox pigments, flame retardants, plasticisers, biocides for paints) | The company expects a construction recovery in 2027 and has removed construction upside from its 2026 guidance |
| Automotive / transport | Medium (lubricant additives, rubber chemicals, AII products) | Reduced to approx. 10% of revenues after the Envalior carve-out (investor estimate, MOI Global 2024) |
| Consumer / personal care / household | Medium (benzoates, aroma chemicals, preservatives, disinfectants) | Most defensive pocket; CP margins rose to 15.4% in FY2025 |
| Water treatment / energy / food | Medium (Lewatit ion-exchange resins) | Structural growth niche |
| Pharma / specialty / electronics | Low but targeted (Saltigo pivot) | Management sees these as higher-margin growth markets for Saltigo |
| Electronics, E&E, plastics (flame retardants) | Medium | Bromine and phosphorus flame retardants |
The company has repeatedly identified agrochemicals, construction and automotive as the end-markets that drove the 2023–2025 downturn. The CEO's comment on Q3 2025 named these three as the most difficult.
Independent characterisation. Despite the "specialty" label, LANXESS is in practice a hybrid. Roughly 40% of sales (Consumer Protection plus parts of Specialty Additives) behave like true specialties, with pricing power, low capital intensity and 13–16% margins. Roughly 30% (Advanced Intermediates) remains a scale- and energy-intensive commodity-to-semi-specialty business that is exposed to Asian overcapacity and German energy costs.
The group's EBITDA margin pre exceptionals has compressed from 13.4% (FY2021, continuing operations) to 9.0% (FY2025). This is well below specialty peers and is the core reason for the de-rating.
Strategy
Stated strategic themes (paraphrased from FY2025 communications and the 2024 Annual Report)
-
Pure-play specialty chemicals. With the Urethane sale, LANXESS describes its exit from plastics and polymers as complete. The portfolio is focused on consumer protection, additives and intermediates.
-
"Control the controllables." The CEO's guiding principle for 2026: keep cutting costs, streamline processes and open up new market opportunities.
-
Deleveraging and return to solid investment-grade metrics. Explicitly stated after the Moody's downgrade and the June 2026 bond issue. The company targets net financial debt below 2.5x EBITDA pre (per August 2026 coverage), supported by Envalior monetisation, tight capex and working capital.
-
Portfolio de-risking away from commoditised segments. Examples include Saltigo's pivot from generic agro toward pharma, specialty and electronic chemicals, and closure of uncompetitive assets such as Widnes and hexane oxidation.
-
Sustainability. Climate neutrality by 2040 (Scope 1+2), expansion of the Scopeblue portfolio, and full voluntary ESRS reporting.
Initiative register (last 24 months)
| Initiative | Announced | Scope | Financial target | Status |
|---|---|---|---|---|
| FORWARD! action plan | 2,023 | Global cost and job reductions (approx. 870 jobs) | EUR 150m permanent annual savings | Fully run-rate since end-2025 |
| Production network optimisation | 14 Aug 2025 | Widnes closure (2026), aroma-chemicals network, El Dorado bromine efficiency; earlier Krefeld hexane oxidation closure | EUR 50m annual savings from end-2027 | In execution |
| Additional cost programme | Flagged Nov 2025; detailed 19 Mar 2026 | 550 jobs (about two-thirds in Germany, mainly administrative) plus strict cost discipline | EUR 100m annual savings by end-2028 | In execution |
| Short-term labour cost measures | Mar 2026 | 35-hour week for tariff employees through end-2026; no base-salary increase for management and non-tariff staff | Not quantified separately | Active |
| Saltigo capacity restructuring | 7 Aug 2026 | Adjust capacity; reduce agro dependence; pivot to pharma, specialty and electronics | EUR 20m annual savings from 2028 | Announced |
| Envalior exit | 23 Sep 2025 | Put / right to offer the 40.94% stake | Base price approx. EUR 1.2bn plus EUR 220m shareholder loan; proceeds described by management as a high three-digit million range depending on performance | Deferred to 2027/2028 after Advent's 2026 decline |
| Refinancing | Jun 2026 | EUR 500m five-year 4.375% bond | Secures October 2026 maturity | Completed |
| Price increases | 2,026 | e.g. Lewatit +6–8% | Margin protection | Implemented |
Aggregate structural savings target. EUR 150m additional by end-2028 (EUR 100m + EUR 50m), on top of the EUR 150m FORWARD! already achieved. In 2026, EUR 65m of savings is expected, weighted to H2.
Medium-term targets and guidance
| Item | Guidance / target |
|---|---|
| FY2026 EBITDA pre | EUR 450–550m (set March 2026; confirmed May and August 2026) |
| Q3 2026 EBITDA pre | EUR 130–150m |
| Leverage | Net financial debt below 2.5x EBITDA pre (target; per August 2026 call coverage) |
| Capital increase | "Not on our agenda" (CEO, March 2026) |
| Older mid-term margin ambitions (e.g. 2025 targets from pre-2023 capital markets days) | Not achieved; superseded |
Products & Services
LANXESS does not disclose revenue by product line or by brand, and pricing is not publicly disclosed for any line. Launch years are given only where known; otherwise products are mature lines dating from Bayer or acquired heritage.
Consumer Protection
| Business unit / product line | Description & key capabilities | Flagship brands / offerings | Target customers | Heritage / latest notable event |
|---|---|---|---|---|
| Material Protection Products: biocides & preservatives | Active ingredients and formulations protecting coatings, wood, plastics, building materials, technical fluids, and personal-care and household products against microbial degradation | Preventol (material protection), Mergal (in-can preservation); former IFF Microbial Control actives (including isothiazolinone and other preservative chemistries) | Paint and coatings, construction materials, home and personal care, industrial water and fluids | Strengthened by the IFF Microbial Control acquisition (2022) |
| MPP: disinfection & hygiene | Broad-spectrum disinfectants for animal health / biosecurity, institutional hygiene, aquaculture | Virkon, Rely+On (acquired from Chemours, 2016, approx.); INTACE and Theseo animal-hygiene ranges (2020, approx.) | Livestock and veterinary, institutional cleaning, food processing | Animal-hygiene franchise expanded through the 2020 bolt-ons |
| MPP: wood protection & agro-adjacent actives | Wood preservatives, antifouling, fungicidal actives | Preventol wood-protection grades | Wood treaters, coatings | Mature |
| Flavors & Fragrances: benzoates & benzoic acid | Benzoic acid, sodium and potassium benzoate (food and beverage preservation), benzyl derivatives | Purox (benzoates); Kalama benzoic acid | Food and beverage, feed, pharma, personal care | Emerald Kalama heritage (2021) |
| Flavors & Fragrances: aroma chemicals | Aroma chemicals (e.g. benzyl alcohol and derivatives, cinnamic derivatives, menthol-related intermediates per company materials) | Kalama aroma chemicals; Rotterdam and Kalama (US) assets | Flavour and fragrance houses, consumer brands | Network streamlining announced Aug 2025 |
| Flavors & Fragrances: benzoate plasticisers | Non-phthalate benzoate plasticisers for adhesives, sealants, flooring | K-Flex (Emerald Kalama heritage) | Adhesives, sealants, vinyl | Mature |
| Liquid Purification Technologies | Ion-exchange resins and adsorbers for water treatment, ultra-pure water (power, semiconductors), hydrometallurgy, food processing | Lewatit (ion-exchange resins), Lewatit FO iron-oxide adsorbers | Utilities, power, electronics, food and sugar, mining | List-price increase of 6–8% in spring 2026 |
| Saltigo: custom manufacturing | Exclusive and custom synthesis of agro actives and intermediates, pharma intermediates and fine chemicals. Multipurpose plants in Leverkusen (ZeTO technical centre) and Dormagen. | Exclusive Synthesis, Toll Manufacturing | Agro majors (70–80% of sales), pharma, specialty and electronic chemicals | Capacity restructuring announced Aug 2026, targeting EUR 20m annual savings from 2028 and a pivot toward pharma, specialty and electronic chemicals |
Specialty Additives
| Business unit / product line | Description & key capabilities | Flagship brands / offerings | Target customers | Heritage / latest notable event |
|---|---|---|---|---|
| Polymer Additives: bromine flame retardants & bromine chain | Integrated bromine extraction from Arkansas brines (El Dorado); brominated flame retardants; clear brine fluids and bromine derivatives | Chemtura heritage brands (e.g. Emerald Innovation polymeric FR, per company materials); bromine and clear brine fluids | Electronics and electrical, construction insulation, oil and gas completion fluids | El Dorado efficiency programme (by end-2026) |
| Polymer Additives: phosphorus flame retardants | Halogen-free and organophosphorus flame retardants for PU foams, PVC, engineering plastics | Disflamoll, Levagard, Reofos (Chemtura heritage) | PU foam and furniture, construction, E&E | Mature |
| Polymer Additives: plasticisers | Specialty and phthalate-free plasticisers | Mesamoll, Adimoll, Uniplex | PVC, rubber, sealants, adhesives | Mature |
| Lubricant Additives Business | Additive components and packages: antiwear, extreme pressure, antioxidants, synthetic base stocks, greases | Additin; Chemtura-heritage synthetic esters and PAO products | Lubricant blenders, OEMs, industrial and metalworking fluids | Mature; EV transition shifts the mix toward industrial |
| Rheinchemie / Rubber Additives | Rubber chemicals (accelerators, antioxidants), pre-dispersed chemicals, process aids, tyre-curing bladders, release agents | Vulkacit, Vulkanox, Rhenogran, Aflux, Rhenodiv, Rhenoshape | Tyre and technical-rubber producers | Mature |
| Urethane Systems (divested 1 Apr 2025) | PU prepolymers and systems | Adiprene, Vibrathane (now with UBE) | — | Sold to UBE; EV EUR 460m |
Advanced Intermediates
| Business unit / product line | Description & key capabilities | Flagship offerings | Target customers | Heritage / latest notable event |
|---|---|---|---|---|
| Advanced Industrial Intermediates: aromatic network | Benzene and toluene derivatives, chlorination and nitration chains, nitro- and chloro-aromatics, aromatic amines, benzyl products | Integrated Verbund at Leverkusen / Krefeld-Uerdingen / Brunsbüttel (Germany) and Nagda (India) | Agrochemicals, dyes and pigments, rubber chemicals, pharma, coatings | Hexane oxidation at Krefeld-Uerdingen closed Q2 2025 |
| AII: amines & specialty intermediates | Aliphatic and aromatic amines, methylamines, specialty building blocks | — | Agro, pharma, water treatment, rubber | Mature |
| Inorganic Pigments | Synthetic iron oxide pigments (red, yellow, black), chromium oxide green; granulated and micronised grades | Bayferrox, Colortherm, Bayferrox Scopeblue (low-CO2 grades) | Construction (concrete, pavers), coatings, plastics | Chromium oxide production at Krefeld-Uerdingen continued (Aug 2024 decision); Porto Feliz (Brazil) and Ningbo (China) plants |
Cross-portfolio sustainability label
Scopeblue is LANXESS's label for products with a significantly reduced carbon footprint or a high share of circular or bio-based raw materials. Applications include Bayferrox, Lewatit and benzoates, among others. The 2025 Sustainability Report highlights an expansion of the Scopeblue portfolio.
Equity-accounted investment: Envalior (not consolidated)
Envalior is the engineering-materials JV formed from LANXESS HPM (Durethan, Pocan, Tepex) and DSM Engineering Materials. LANXESS holds 40.94% and Advent International the remainder. LANXESS recognises its share of Envalior's net income in the at-equity line.
Product Portfolio
| Business unit / product line | Description & key capabilities | Flagship brands / offerings | Target customers | Heritage / latest notable event |
|---|---|---|---|---|
Material Protection Products: biocides & preservatives | Active ingredients and formulations protecting coatings, wood, plastics, building materials, technical fluids, and personal-care and household products against microbial degradation | Preventol (material protection), Mergal (in-can preservation); former IFF Microbial Control actives (including isothiazolinone and other preservative chemistries) | Paint and coatings, construction materials, home and personal care, industrial water and fluids | Strengthened by the IFF Microbial Control acquisition (2022) |
MPP: disinfection & hygiene | Broad-spectrum disinfectants for animal health / biosecurity, institutional hygiene, aquaculture | Virkon, Rely+On (acquired from Chemours, 2016, approx.); INTACE and Theseo animal-hygiene ranges (2020, approx.) | Livestock and veterinary, institutional cleaning, food processing | Animal-hygiene franchise expanded through the 2020 bolt-ons |
MPP: wood protection & agro-adjacent actives | Wood preservatives, antifouling, fungicidal actives | Preventol wood-protection grades | Wood treaters, coatings | Mature |
Flavors & Fragrances: benzoates & benzoic acid | Benzoic acid, sodium and potassium benzoate (food and beverage preservation), benzyl derivatives | Purox (benzoates); Kalama benzoic acid | Food and beverage, feed, pharma, personal care | Emerald Kalama heritage (2021) |
Flavors & Fragrances: aroma chemicals | Aroma chemicals (e.g. benzyl alcohol and derivatives, cinnamic derivatives, menthol-related intermediates per company materials) | Kalama aroma chemicals; Rotterdam and Kalama (US) assets | Flavour and fragrance houses, consumer brands | Network streamlining announced Aug 2025 |
Flavors & Fragrances: benzoate plasticisers | Non-phthalate benzoate plasticisers for adhesives, sealants, flooring | K-Flex (Emerald Kalama heritage) | Adhesives, sealants, vinyl | Mature |
Liquid Purification Technologies | Ion-exchange resins and adsorbers for water treatment, ultra-pure water (power, semiconductors), hydrometallurgy, food processing | Lewatit (ion-exchange resins), Lewatit FO iron-oxide adsorbers | Utilities, power, electronics, food and sugar, mining | List-price increase of 6–8% in spring 2026 |
Saltigo: custom manufacturing | Exclusive and custom synthesis of agro actives and intermediates, pharma intermediates and fine chemicals. Multipurpose plants in Leverkusen (ZeTO technical centre) and Dormagen. | Exclusive Synthesis, Toll Manufacturing | Agro majors (70–80% of sales), pharma, specialty and electronic chemicals | Capacity restructuring announced Aug 2026, targeting EUR 20m annual savings from 2028 and a pivot toward pharma, specialty and electronic chemicals |
| Business unit / product line | Description & key capabilities | Flagship brands / offerings | Target customers | Heritage / latest notable event |
|---|---|---|---|---|
Polymer Additives: bromine flame retardants & bromine chain | Integrated bromine extraction from Arkansas brines (El Dorado); brominated flame retardants; clear brine fluids and bromine derivatives | Chemtura heritage brands (e.g. Emerald Innovation polymeric FR, per company materials); bromine and clear brine fluids | Electronics and electrical, construction insulation, oil and gas completion fluids | El Dorado efficiency programme (by end-2026) |
Polymer Additives: phosphorus flame retardants | Halogen-free and organophosphorus flame retardants for PU foams, PVC, engineering plastics | Disflamoll, Levagard, Reofos (Chemtura heritage) | PU foam and furniture, construction, E&E | Mature |
Polymer Additives: plasticisers | Specialty and phthalate-free plasticisers | Mesamoll, Adimoll, Uniplex | PVC, rubber, sealants, adhesives | Mature |
Lubricant Additives Business | Additive components and packages: antiwear, extreme pressure, antioxidants, synthetic base stocks, greases | Additin; Chemtura-heritage synthetic esters and PAO products | Lubricant blenders, OEMs, industrial and metalworking fluids | Mature; EV transition shifts the mix toward industrial |
Rheinchemie / Rubber Additives | Rubber chemicals (accelerators, antioxidants), pre-dispersed chemicals, process aids, tyre-curing bladders, release agents | Vulkacit, Vulkanox, Rhenogran, Aflux, Rhenodiv, Rhenoshape | Tyre and technical-rubber producers | Mature |
Urethane Systems (divested 1 Apr 2025) | PU prepolymers and systems | Adiprene, Vibrathane (now with UBE) | — | Sold to UBE; EV EUR 460m |
| Business unit / product line | Description & key capabilities | Flagship offerings | Target customers | Heritage / latest notable event |
|---|---|---|---|---|
Advanced Industrial Intermediates: aromatic network | Benzene and toluene derivatives, chlorination and nitration chains, nitro- and chloro-aromatics, aromatic amines, benzyl products | Integrated Verbund at Leverkusen / Krefeld-Uerdingen / Brunsbüttel (Germany) and Nagda (India) | Agrochemicals, dyes and pigments, rubber chemicals, pharma, coatings | Hexane oxidation at Krefeld-Uerdingen closed Q2 2025 |
AII: amines & specialty intermediates | Aliphatic and aromatic amines, methylamines, specialty building blocks | — | Agro, pharma, water treatment, rubber | Mature |
Inorganic Pigments | Synthetic iron oxide pigments (red, yellow, black), chromium oxide green; granulated and micronised grades | Bayferrox, Colortherm, Bayferrox Scopeblue (low-CO2 grades) | Construction (concrete, pavers), coatings, plastics | Chromium oxide production at Krefeld-Uerdingen continued (Aug 2024 decision); Porto Feliz (Brazil) and Ningbo (China) plants |
Financial Narrative
Basis. FY2021 figures are continuing operations as restated in the FY2022 release (excluding HPM). FY2022 to FY2025 are as reported.
Income statement
Notes on sources and derivations:
FY2021: total net income of 267 is derived from EPS of EUR 3.09 multiplied by approx. 86.3m shares; EPS per roic.ai.
FY2023: total net income of +443 includes the Envalior transaction gain. EPS of 5.13 is on total net income; on continuing operations EPS was approx. −9.76.
FY2024 and FY2025: continuing and total net income are assumed equal because no discontinued operations were reported in the sources reviewed. Net loss figures are per MarketScreener and Simply Wall St, consistent with EPS of −2.05 and −6.68.
Dividends: these are dividends for each fiscal year, paid in the following May. The FY2025 dividend of EUR 0.10 was paid on 27 May 2026.
Verified points are:
Margins and growth (%)
FY2021 growth rates are shown as 0.0 because a restated FY2020 continuing-operations base is not available. The FY2023 net margin is distorted by the Envalior gain.
CAGR FY2021–FY2025 (derived). Sales −1.8% per year; EBITDA pre −11.1% per year.
Quarterly P&L, 2025–2026
Notes on derivations and verification:
-
Q4 2025 sales, EBITDA pre, margin and net income are derived as FY less 9M. The Q4 2025 net loss of approx. −398 implies a large impairment / at-equity charge; management cited an asset impairment recorded in both LANXESS's and Envalior's books.
-
Q2 2026 net income is per the Q2 2026 call summary (Quartr).
-
2025 quarterly free cash flow is approximate: Q1 2025 and Q3 2025 are derived from 9M FCF of −94 and Q2 FCF of +31, and Q4 2025 from an approximate FY2025 FCF of −30 (roic.ai).
Adjusted EPS: Q2 2026 EUR 0.51 (Q2 2025: EUR 0.59); H1 2026 EUR 0.01 (H1 2025: EUR 0.82).
Balance sheet
Machine-charting should exclude 0 values in this table.
Additional verified points:
-
Total assets: EUR 9,512m (31 Mar 2025); EUR 8,427m (30 Jun 2025); EUR 8,183m (30 Sep 2025).
-
Equity ratio: 47.3% (31 Dec 2024); 47.4% (30 Jun 2025); approx. 48% (30 Sep 2025).
-
Net financial liabilities: EUR 2,049m at 30 June 2026.
Liquidity and debt structure (March–June 2026 disclosures).
-
Cash and near-cash of approx. EUR 0.5bn.
-
Undrawn committed lines of EUR 1.35bn: an EUR 800m sustainability-linked RCF maturing 2030 (plus a one-year extension option) and EUR 550m of bilateral lines.
-
No financial covenants on any instrument.
-
Average fixed bond coupon approx. 1% before the June 2026 issue.
Cash flow
Notes:
- The FY2022 (−220) and FY2023 (526) values are the company's reported free-cash-flow metric per the FY2023 release, quoted as "EUR 526 million in 2023, after minus EUR 220 million in the previous year".
Other cash-flow points.
-
Operating cash flow: Q1 2025 EUR −66m; Q2 2025 EUR 96m; Q3 2025 EUR 50m.
-
Dividends paid: approx. EUR 8.6m per year for FY2023 to FY2025 payouts (EUR 0.10 × approx. 86.3m shares, derived). This compares with approx. EUR 91m per year at EUR 1.05 (derived).
-
Buybacks: none during FY2021–FY2025 in the sources reviewed.
Ratios
FY2024 and FY2025 FCF conversion are based on approximate FCF.
The following indicative values can be derived:
-
FY2024 ROE of approx. −3.9% (net income of −177 on equity of approx. 4,593).
-
FY2024 asset turnover of approx. 0.66x (6,366 / 9,711).
-
Interest coverage looks structurally comfortable on cash interest because of the approx. 1% average bond coupon. The marginal cost of debt is now 4.375% on the 2031 bond.
Commentary on trends, inflections and drivers
FY2021–FY2022: inflationary boom. Continuing sales grew 32.6% to EUR 8.09bn in FY2022. The drivers were (i) pass-through of energy and raw-material inflation and (ii) consolidation of IFF Microbial Control and Emerald Kalama. EBITDA pre rose only 14.1%, however, and the margin compressed from 13.4% to 11.5% as volume weakened in Q4 2022. The acquisitions doubled leverage, with net financial debt reaching EUR 3.8bn. This set up the balance-sheet stress of the following three years.
FY2023: multi-crisis year. Destocking across agro, construction and coatings, combined with German energy costs, cut EBITDA pre by 44.9% to EUR 512m. The Envalior closing produced a headline net income of EUR +443m. Continuing operations, however, lost EUR 843m after a EUR 406m goodwill impairment and an at-equity charge. Aggressive working-capital release (NWC from EUR 2.0bn to EUR 1.4bn) delivered FCF of EUR 526m, and net debt fell 35% to EUR 2.5bn. The dividend was cut by 90%.
FY2024: false dawn. EBITDA pre recovered 19.9% to EUR 614m on restocking and FORWARD! savings. The recovery was concentrated in Advanced Intermediates (EUR 210m, 11.6% margin) and was not sustained.
FY2025: second leg down. Sales fell 10.9% and EBITDA pre fell 16.9% to EUR 510m. The causes were volume and price declines of about 3–4% each, the Urethane deconsolidation, FX headwinds, a EUR 10m chlorine-supply disruption and Asian price pressure in intermediates. Guidance was cut twice (August and November 2025). The FY2025 net loss of EUR 577m, against EPS of −2.05 in FY2024, reflects impairments including on the Envalior carrying value and restructuring charges. Net debt nonetheless fell to EUR 2.02bn thanks to the Urethane proceeds.
2026: self-help plus a partial cyclical uptick. Q1 2026 was the trough (EBITDA pre EUR 94m, margin 6.8%). Q2 2026 rebounded to EUR 152m, helped in part by temporary Middle East supply disruptions that favoured reliable European suppliers. Management characterised the improvement as possibly not a trend. It expects EUR 65m of cost savings in 2026, weighted to H2. Quarterly guidance implies a Q4 2026 EBITDA pre range of approx. EUR 64–164m (derived).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Business units (per Annual Report 2024 structure) | Principal applications |
|---|---|---|
Consumer Protection | Material Protection Products (MPP, incl. former IFF Microbial Control); Flavors & Fragrances (incl. former Emerald Kalama); Liquid Purification Technologies (LPT); Saltigo (custom manufacturing) | Biocides, disinfectants, preservatives; benzoic acid, benzoates, aroma chemicals; ion-exchange resins; agro and pharma custom synthesis |
Specialty Additives | Polymer Additives (flame retardants, plasticisers); Lubricant Additives Business; Rheinchemie / Rubber Additives. Urethane Systems sat here until its sale on 1 April 2025. | Flame retardants for E&E and construction; lubricant additive packages and components; rubber chemicals, release agents |
Advanced Intermediates | Advanced Industrial Intermediates (AII); Inorganic Pigments (IPG) | Aromatic, nitro, chloro and amine intermediates for agro, coatings, rubber and pharma; Bayferrox iron oxide and chromium oxide pigments for construction and coatings |
Reconciliation / Other | Corporate functions, group services, consolidation | Negative approx. EUR 109–128m EBITDA pre per year (derived) |
Segment sales (EUR Mn)
| Segment sales (EUR Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Consumer Protection sales | 2,340 | 2,081 | 1,889 |
Specialty Additives sales | 2,325 | 2,209 | 2,056 |
Advanced Intermediates sales | 1,775 | 1,804 | 1,653 |
Reconciliation / other sales (derived) | 274 | 272 | 75 |
Group sales | 6,714 | 6,366 | 5,673 |
Segment EBITDA pre (EUR Mn)
| Segment EBITDA pre (EUR Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Consumer Protection EBITDA pre | 310 | 286 | 290 |
Specialty Additives EBITDA pre | 209 | 227 | 201 |
Advanced Intermediates EBITDA pre | 121 | 210 | 128 |
Reconciliation (derived) | -128 | -109 | -109 |
Group EBITDA pre | 512 | 614 | 510 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Segment metric (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Consumer Protection EBITDA pre margin | 13.2 | 13.7 | 15.4 |
Specialty Additives EBITDA pre margin | 9.0 | 10.3 | 9.8 |
Advanced Intermediates EBITDA pre margin | 6.8 | 11.6 | 7.7 |
Consumer Protection sales growth YoY | -1.1 | -11.1 | -9.2 |
Specialty Additives sales growth YoY | -21.7 | -5.0 | -6.9 |
Advanced Intermediates sales growth YoY | -26.4 | 1.6 | -8.4 |
Consumer Protection share of group sales | 34.9 | 32.7 | 33.3 |
Specialty Additives share of group sales | 34.6 | 34.7 | 36.2 |
Advanced Intermediates share of group sales | 26.4 | 28.3 | 29.1 |
Revenue by Segment
| Quarterly metric (EUR Mn) | Q1 2025 | Q2 2025 | Q3 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Consumer Protection sales | 513 | 489 | 453 | 458 | 515 |
Specialty Additives sales | 545 | 528 | 505 | 521 | 588 |
Advanced Intermediates sales | 476 | 447 | 377 | 392 | 456 |
Consumer Protection EBITDA pre | 73 | 87 | 72 | 62 | 81 |
Specialty Additives EBITDA pre | 52 | 58 | 45 | 44 | 77 |
Advanced Intermediates EBITDA pre | 40 | 44 | 28 | 27 | 35 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome statement (EUR Mn)
| Income statement (EUR Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Sales | 6,101 | 8,088 | 6,714 | 6,366 | 5,673 |
EBITDA pre exceptionals | 815 | 930 | 512 | 614 | 510 |
Net income, continuing operations | 115 | 184 | -843 | -177 | -577 |
Net income, total (attributable) | 267 | 250 | 443 | -177 | -577 |
EPS basic, total (EUR) | 3.09 | 2.90 | 5.13 | -2.05 | -6.68 |
Dividend per share (EUR) | 1.05 | 1.05 | 0.10 | 0.10 | 0.10 |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
Income before income taxes, FY2022 | EUR 257m | Q4 2023 Financial Summary |
Income before income taxes, FY2023 | EUR −947m | Q4 2023 Financial Summary |
Reported EBITDA, Q4 2023 | EUR −7m | Q4 2023 Financial Summary |
Gross profit, Q3 2025 | EUR 254m (−27.2% YoY) | Quartr |
EBIT, Q3 2025 | EUR −28m | Quartr |
EBIT, Q1 2025 | EUR −23m | Q1 2025 statement |
Market cap | approx. EUR 1.07bn | approx. 86.35m shares |
Enterprise value (excl. pensions) | approx. EUR 3.1bn | Market cap plus NFD of EUR 2,049m (30 Jun 2026) |
EV / EBITDA pre FY2025 | approx. 6.1x | EUR 510m |
EV / EBITDA pre FY2026 guidance midpoint | approx. 6.2x | EUR 500m |
EV / Sales FY2025 | approx. 0.55x | EUR 5,673m |
P/E | Not meaningful (losses) | FY2025 EPS −6.68 |
P/B | approx. 0.25–0.3x (indicative) | Equity of approx. |
Envalior stake vs. market cap | approx. 0.9–1.3x | Stake value approx. EUR 0.95bn (J.P. Morgan) to EUR 1.42bn (base price plus loan) |
Margin / growth (%)
| Margin / growth (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
EBITDA pre margin | 13.4 | 11.5 | 7.6 | 9.6 | 9.0 |
Net margin, total net income (derived) | 4.4 | 3.1 | 6.6 | -2.8 | -10.2 |
Sales growth YoY (derived) | 0.0 | 32.6 | -17.0 | -5.2 | -10.9 |
EBITDA pre growth YoY | 0.0 | 14.1 | -44.9 | 19.9 | -16.9 |
Income Statement and Margin Analysis (%)
| Quarterly P&L (EUR Mn) | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
Sales | 1,601 | 1,466 | 1,338 | 1,268 | 1,378 | 1,561 |
EBITDA pre exceptionals | 133 | 150 | 125 | 102 | 94 | 152 |
EBITDA pre margin (%) | 8.3 | 10.2 | 9.3 | 8.0 | 6.8 | 9.7 |
Net income | -57 | -45 | -77 | -398 | -141 | -53 |
Free cash flow | -125 | 31 | 0 | 64 | -29 | 56 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBalance Sheet and Financial Ratios (x)
| Balance sheet (EUR Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Net financial liabilities | 3,814 | 2,498 | 2,381 | 2,023 |
Total assets | 0 | 0 | 9,711 | 0 |
Equity (derived from equity ratio) | 0 | 0 | 4,593 | 0 |
Net working capital | 2,010 | 1,389 | 0 | 0 |
Cash flow (EUR Mn)
| Cash flow (EUR Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Free cash flow | -220 | 526 | 188 | -30 |
Financial Ratios (x) and Margin Analysis (%)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Net financial debt / EBITDA pre (x, derived) | 4.1 | 4.9 | 3.9 | 4.0 |
Free cash flow / EBITDA pre (%, derived) | -23.7 | 102.7 | 30.6 | -5.9 |
Dividend payout of EBITDA pre (%, derived) | 9.7 | 1.7 | 1.4 | 1.7 |
Region (As Reported) Overview
| Region (as reported) | Relative weight (qualitative, FY2024–FY2025) | Trend and drivers |
|---|---|---|
EMEA excluding Germany | Largest region | Weak construction and coatings demand; destocking 2023 to 2025 |
Germany | Significant home market | Structural weakness in German industrial production; energy costs. The government infrastructure stimulus is an expected 2027 tailwind. |
North America | Large (bromine, Kalama, lubricant additives) | Tariff uncertainty in 2025; El Dorado efficiency programme |
Latin America | Smaller | Agro exposure (Brazil); Porto Feliz pigments |
Asia/Pacific | Significant | Chinese overcapacity is driving price pressure in intermediates and pigments; India (Nagda, Jhagadia) is a growth site |
Share Price History
| Date | Share price (EUR) | Context |
|---|---|---|
Start of 2026 (derived) | 17.6 | Derived from EUR 15.26 on 21 Jul 2026 being −13.4% YTD |
6 Mar 2026 (intraday low) | 13.40 | Advent news; lowest since mid-2009 |
10 Mar 2026 | 13.65 | Post Moody's downgrade |
Spring 2026 (approx.) | 17.98 | After a monthly gain of approx. 31% |
29 May 2026 | 16.84 | Deutsche Bank Hold, price target EUR 17 |
17 Jun 2026 | 16.10 | CEO purchase |
21 Jul 2026 | 15.26 | Mid-summer |
Late Sep 2026 | 12.33 | Scope downgrade |
Capital Markets
| Item | Data |
|---|---|
Coverage | approx. 13–16 analysts providing EPS estimates (theScreener via cash.ch, July 2026) |
Recent actions | MWB Research: Buy, price target EUR 20 (June 2026). Deutsche Bank: Hold, price target EUR 17 (29 May 2026). |
Consensus sales (MarketScreener, mid-2026 snapshot) | FY2026 EUR 5,838m; FY2027 EUR 5,920m; FY2028 EUR 6,102m |
Consensus net income (same) | FY2026 EUR −201m; FY2027 EUR −86m; FY2028 EUR +15m |
Consensus (MarketScreener, mid-2026, EUR Mn) | FY2026 |
Consensus sales | 5,838 |
Consensus net income | -201 |
Dividend per share (EUR)
| Dividend per share (EUR) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividend per share | 1.05 | 1.05 | 0.10 | 0.10 | 0.10 |
Credit Ratings
| Agency | Rating | Outlook | Latest action |
|---|---|---|---|
Moody's | Ba1 | Negative (per June 2026 deal documentation) | Downgraded from Baa3 on 9 Mar 2026 |
Scope | BBB- | Stable | Downgraded from BBB with outlook change from Negative (late September 2026). History: BBB+ (to 2023), BBB/Negative (February 2024), BBB-/Negative (February 2025), upgraded to BBB/Stable (2025, after methodology update) |
S&P | No current solicited rating identified | — | — |
Fitch | No current rating identified | — | — |
Debt Maturity Profile
| Maturity | Amount | Coupon | Status |
|---|---|---|---|
May 2025 | EUR 500m | — | Repaid (Urethane proceeds) |
October 2026 | approx. EUR 500m (EUR 499m outstanding per 2024 investor note) | — | Refinanced by the June 2026 issue |
September 2027 | approx. EUR 500m (EUR 497m per 2024 investor note); Scope cites EUR 600m due 2027 | — | Outstanding; covered by cash and lines per Scope |
December 2029 | EUR 600m (ISIN XS2415386726) | 0.625% | Outstanding; traded below 90% in March 2026 |
2031 (June 2026 issue) | EUR 500m | 4.375% | Outstanding |
Other senior and hybrid instruments | — | — | See FY2025 Annual Report |
Analyst Conclusions
Management guidance
| Item | Guidance |
|---|---|
| FY2026 EBITDA pre | EUR 450–550m (confirmed 7 August 2026) |
| Q3 2026 EBITDA pre | EUR 130–150m, better than the prior year but below Q2 |
| Macro | No further economic momentum expected in core markets for the rest of 2026; construction recovery expected in 2027 |
| Cost savings 2026 | approx. EUR 65m, H2-weighted |
| Implied Q4 2026 EBITDA pre (derived) | approx. EUR 64–164m |
Consensus expects sales to grow modestly (+3% in FY2026 to EUR 5.84bn, +1–3% per year thereafter) and net income to return to breakeven only by FY2028 (MarketScreener mid-2026 snapshot).
Bull case
-
Sum-of-the-parts asymmetry. At about EUR 1.1bn of market cap, the equity is roughly covered by the Envalior stake (EUR 0.95–1.4bn), so the operating business trades near its net debt. An unconditional 2028 put on at least 50% caps the downside of the stake's realisability.
-
Operating leverage plus cost cuts. Q2 2026 showed EBITDA pre +62% QoQ on +13% sales. EUR 150m of additional structural savings by 2028 is roughly 30% of FY2025 EBITDA pre. A return to a mid-cycle EUR 700–800m EBITDA pre would re-rate the shares sharply.
-
Funding stress removed. The October 2026 maturity is refinanced, there are no covenants, EUR 1.35bn of lines is undrawn, insiders bought shares in June 2026, and management has ruled out a capital increase.
Bear case
-
Structural, not cyclical. Scope now calls demand weakness increasingly structural and cites Asian overcapacity. The Advanced Intermediates margin of 7.7% and energy costs may never revert, capping group margins near 9–10%.
-
Deleveraging delayed to 2028. If Advent declines again in 2027, NFD/EBITDA stays around 4x. A Scope downgrade to sub-IG would make LANXESS fully high-yield, with refinancing costs rising from about 1% to about 4.4%+ as the legacy bonds roll.
-
Persistent losses and impairment risk. Consensus sees net losses through FY2027 and a near-zero dividend. Further goodwill and at-equity impairments are possible if Envalior or the acquired consumer-protection businesses underperform.
Catalysts and monitorables (next 12 months)
Q3 2026 results (early November 2026): delivery against the EUR 130–150m guide; FY2026 guidance narrowing; FCF.
FY2026 results (March 2027): 2027 guidance; dividend; progress on EUR 150m savings.
Envalior 2027 purchase window: Advent's call / financing decision at the same price as 2026; Envalior LTM EBITDA development, which drives the price adjustment.
Rating actions: Moody's outlook (negative); Scope BBB- floor.
Energy prices and European chemicals demand: Ifo chemical confidence; German infrastructure-stimulus disbursement.
Saltigo restructuring execution: and pharma or electronics contract wins.
Portfolio moves: any disposal in Advanced Intermediates or pigments; take-private speculation (unconfirmed).
Analyst verdict
LANXESS enters late 2026 as a balance-sheet-constrained turnaround with a hidden asset. Its strategic transformation into a specialty company is complete on paper: rubber, plastics and urethanes are gone. The resulting portfolio, however, has not delivered specialty economics. FY2025 EBITDA pre of EUR 510m at a 9.0% margin is the lowest level since the carve-out era once portfolio changes are adjusted for. FY2026 guidance of EUR 450–550m implies no earnings recovery this year.
The Consumer Protection segment is a genuine quality asset, with margins above 15%. It is offset by Advanced Intermediates, whose economics are dictated by German energy prices and Chinese capacity.
The decisive variable is not operations but capital structure and timing. Advent's March 2026 refusal to fund the Envalior purchase pushed the most important deleveraging lever out to 2027 or 2028. It also cost LANXESS its Moody's investment-grade rating, and Scope has since cut to BBB-.
Management has responded credibly:
-
€150m of new structural savings;
-
550 job cuts;
-
a refinanced October 2026 maturity;
-
covenant-free liquidity of €1.35bn;
-
conspicuous insider buying.
Liquidity risk is low, but leverage risk and dilution of equity value over time are real.
At roughly EUR 12–13 per share, the market is ascribing little or no value to the operating businesses beyond their net debt once the Envalior stake is credited at JPMorgan's EUR 950m estimate. That creates asymmetric upside if three conditions are met: (i) H2 2026 cost savings land, (ii) European construction recovers in 2027 as management expects, and (iii) the Envalior exit is secured in 2027. The structural-decline thesis on European chemicals, however, is gaining official endorsement from rating agencies.
**Overall assessment: speculative recovery situation. The near-term signposts are delivery of Q3 and Q4 2026 against guidance and the Scope rating floor. Absent progress on both, the equity likely remains range-bound near asset-backing levels.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | On board since | Background |
|---|---|---|---|
Matthias Zachert | Chairman of the Board of Management (CEO) | 1 Apr 2014 | LANXESS CFO (2004 to 2011), then CFO of Merck KGaA (2011 to 2014). Earlier finance roles at Hoechst/Aventis and Kamps. |
Oliver Stratmann | Member, CFO | 1 Sep 2023 | Mandate extended by five years from 1 Sep 2026. Praised by the Supervisory Board chair for capital-markets expertise. |
Dr. Hubert Fink | Member of the Board of Management | approx. 2015 | — |
Frederique van Baarle | Member of the Board of Management | approx. | — |
Board of Directors — Dr. Rainier van Roessel
| Name | Role | Notes |
|---|---|---|
Dr. Rainier van Roessel (68) | Chairman (since May 2024; re-elected 21 May 2026 for a four-year term) | Joined the Supervisory Board in 2022. LANXESS Board of Management member and Labour Director from 2007 to end-2019; began his career at Bayer. Former-executive-to-chair transition is a governance consideration under the German Corporate Governance Code's independence criteria. |
Uta Kemmerich-Keil (59) | Shareholder representative (elected 21 May 2026) | Former head of P&G International Personal Healthcare |
Dr. Heike Hanagarth | Former shareholder representative (2016 to May 2026) | Did not stand for re-election |
Deputy Chair | Employee representative | — |
Board & Management Changes
| Date | Change |
|---|---|
Sep 2023 | Oliver Stratmann becomes CFO |
May 2024 | Rainier van Roessel becomes Chairman of the Supervisory Board |
| 2025 | Stratmann's CFO mandate renewed for five years from 1 Sep 2026 |
21 May 2026 | AGM: van Roessel re-elected; Kemmerich-Keil succeeds Hanagarth |
Competitive Landscape
Competitors by Segment
| Segment / business | Principal competitors | Relative positioning of LANXESS |
|---|---|---|
MPP (biocides, preservatives, disinfection) | Lonza Specialty Ingredients (now Arxada, private); Troy (acquired by Arxada); Thor Group; Clariant (selected); Vink Chemicals; Solvay/Syensqo (selected) | Top-tier global player after IFF Microbial Control; strong regulatory dossier moat |
Flavors & Fragrances (benzoates, aroma chemicals) | Eastman (benzoic acid / benzoates, selected); Symrise and Givaudan (aroma molecules, partly captive); Chinese benzoate producers (e.g. Wuhan Youji) | Leading Western benzoic-acid producer; exposed to Chinese pricing |
Liquid Purification Technologies | DuPont Water Solutions; Purolite (Ecolab); Mitsubishi Chemical; Chinese producers (e.g. Sunresin) | — |
Saltigo (custom manufacturing) | Lonza (pharma CDMO), Siegfried, Dottikon ES, CABB, WeylChem, Indian and Chinese CMOs (e.g. PI Industries, Divi's) | Mid-sized European agro CMO; pivoting to pharma |
Polymer Additives (flame retardants) | Albemarle (bromine FR), ICL Group (bromine), Clariant (phosphorus FR), Chinese FR producers | Third Western bromine player behind Albemarle and ICL |
Lubricant Additives | Lubrizol (Berkshire Hathaway), Infineum, Chevron Oronite, Afton (NewMarket), BASF | Niche component supplier, not a full-package major |
Rheinchemie / rubber additives | Eastman (selected), Sennics (China), Kumho Petrochemical, Arkema (selected) | Specialist in pre-dispersed and bladder niches |
Advanced Industrial Intermediates | BASF, Covestro (selected), Chinese and Indian aromatic intermediates producers (e.g. Aarti Industries) | Integrated German Verbund; cost-disadvantaged on energy |
Inorganic Pigments | Chinese iron-oxide producers (e.g. Zhejiang Huayuan, Cathay Industrial), Venator (selected), Tronox (TiO2, adjacent) | Global leader in synthetic iron oxide (Bayferrox, company claim); faces Chinese overcapacity |
Peer Comparison FY2025
| Company | FY revenue (approx.) | Adj. EBITDA margin (approx.) | Revenue growth (approx.) | R&D intensity |
|---|---|---|---|---|
LANXESS (FY2025) | EUR 5.7bn | 9.0% | −10.9% | — |
Evonik (FY2024) | EUR 15.2bn | approx. 13–14% | approx. 0% | approx. 3% |
Clariant (FY2024) | CHF 4.2bn | approx. 16–17% | approx. −4% | approx. 2–3% |
Albemarle (FY2024) | USD 5.4bn | Volatile (lithium-driven) | approx. −44% | approx. 1–2% |
ICL Group (FY2024) | USD 6.8bn | approx. 20% | approx. −8% | approx. 1% |
